#Seegene #CURECA #PCR System

Seegene Unveils CURECA™: The Future of PCR Automation

In a groundbreaking presentation at the ESCMID Global 2025, Seegene Inc., a global leader in molecular diagnostics, showcased an innovative concept video introducing CURECA™, a next-generation fully automated PCR system. This system is poised to transform laboratory workflows by integrating the entire PCR process, from sample pre-treatment to result analysis, into a seamless automated experience.

Developing Automation for a Healthier World

CURECA™ stands for Continuous Unlimited Random access Expandable and Customizable full Automation. This cutting-edge solution reflects Seegene's mission to establish new global standards in diagnostic automation and to promote a vision of a world free from all diseases. Expected to operate 24/7, CURECA™ aims to eliminate human error, speeding up testing processes while ensuring high accuracy.

Product highlights include two main components: the Customizable Pre-treatment System (CPS) and the Customizable and Expandable Full Automation (CEFA). The CPS is designed for handling various types of biological samples such as feces, urine, blood, and sputum, marking a shift from manual processes traditionally employed in laboratories. Its key capabilities include sample selection, centrifugation, vortexing, and thermal treatment.

Notably, the CPS can function independently, making it adaptable to a variety of laboratory analyses beyond PCR, such as hematology and immunodiagnostics, significantly expanding its applicability.

The Journey Towards Automation

The modular design of CURECA™ grants laboratories substantial flexibility, allowing them to configure the system in accordance with their specific operational needs. The goal is to facilitate continuous and high-throughput PCR testing, thereby supporting the global healthcare infrastructure and advancing public health.

The CURECA™ concept was introduced via a detailed video that demonstrated the entire workflow automation process, from sample loading and pre-treatment to nucleic acid extraction and analytical setup for PCR amplification. The system's adaptability to diverse laboratory environments further emphasizes its potential.

Dr. Jong-Yoon Chun, founder and CEO of Seegene, shared, “Until now, there has been no system capable of fully automating the pre-treatment phase for all types of biological samples, which has limited true automation in molecular diagnostics.” The former manual approach necessitated skilled lab professionals, which made it time-consuming and prone to errors.

With CURECA™, Seegene aims not only to elevate standards but also to reshape the future of molecular diagnostics. The company is committed to improving access to advanced MDx technologies worldwide, significantly enhancing global healthcare outcomes.

Integrating Advanced Technologies

At the ESCMID Global 2025 conference, Seegene's presentation wasn’t limited to CURECA™. The company also showcased its portfolio of syndromic real-time PCR tests, aligned with the theme